Antiviral activity of lipoxygenase against severe fever with thrombocytopenia syndrome virus

References

[1] Chrisnasari R, Hennebelle M, Vincken JP et al. Bacterial lipoxygenases: biochemical characteristics, molecular structure and potential applications. Biotechnol Adv 2022;61:108046.

[2] Horio Y, Isegawa Y, Shichiri M. Daidzein phosphorylates and activates 5-lipoxygenase via the MEK/ERK pathway: a mechanism for inducing the production of 5-lipoxygenase metabolite that inhibit influenza virus intracellular replication. J Nutr Biochem 2023;114:109276.

[3] Kuhn H, Banthiya S, van Leyen K. Mammalian lipoxygenases and their biological relevance. Biochim Biophys Acta 2015;1851:308–330.

[4] Li H, Zhang LK, Li SF et al. Clinical effect and antiviral mechanism of T-705 in treating severe fever with thrombocytopenia syndrome. Cell Res 2019;29:739–753.

[5] Li H, Jiang XM, Cui N et al. Calcium channel blockers reduce severe fever with thrombocytopenia syndrome virus (SFTSV) related fatality. Signal Transduct Target Ther 2021;6:145.

[6] Liu Q, He B, Huang SY et al. Severe fever with thrombocytopenia syndrome, an emerging tick-borne zoonosis. Lancet Infect Dis 2014;14:763–772.

[7] Mashima R, Okuyama T. The role of lipoxygenases in pathophysiology;new insights and future perspectives. Redox Biol 2015;6:297–310.

[8] Morita M, Kuba K, Ichikawa A et al. The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. Cell 2013;153:112–125.

[9] Prigge ST, Boyington JC, Gaffney BJ et al. Structure conservation in lipoxygenases: structural analysis of soybean lipoxygenase-1 and modeling of human lipoxygenases. Proteins 1996;24:275–291.

[10] Qin T, Ma R, Yin Y et al. Catalytic inactivation of influenza virus by iron oxide nanozyme. Theranostics 2019;9:6920–6935.

[11] Sun Y, Qi Y, Liu C et al. Nonmuscle myosin heavy chain IIA is a critical factor contributing to the efficiency of early infection of severe fever with thrombocytopenia syndrome virus. J Virol 2014;88:237–248.

[12] Yu XJ, Liang MF, Zhang SY et al. Fever with thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med 2011;364:1523–1532.

[13] Yuan SF, Wen L, Chik KK et al. In silico structure-based design of antiviral peptides targeting the severe fever with thrombocytopenia syndrome virus glycoprotein gn. Viruses 2021;13:2047.

[14] Zhang L, Peng X, Wang Q et al. CCR2 is a host entry receptor for severe fever with thrombocytopenia syndrome virus. Sci Adv 2023;9:eadg6856.

RIGHTS & PERMISSIONS

The Author(s) 2024. Published by Oxford University Press on behalf of Higher Education Press.